HOME >> MEDICINE >> NEWS
Study examined switching rates between Allegra® (fexofenadine HCl) and Claritin®

CHICAGO, Il., November 13, 1999 - A higher percentage of seasonal allergic rhinitis (SAR) patients switched to Allegra® (fexofenadine HCl) from Claritin® (loratadine) than vice versa in the spring and fall of 1997 and 1998, according to the results of a study of more than 33,000 patients presented at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI).

The findings are based on "Prescribing Patterns of Non-sedating Antihistamines and Daily Dose Differences in a Managed Care Population," a study that evaluated the continuity of allergy treatment by drug and by allergy season (spring, fall 1997- 1998). The retrospective study analyzed data from physicians' claims from 12 United Healthcare health plans.

During the study period, an average of 12.6 percent of patients taking Claritin switched to Allegra versus 10.0 percent of patients who switched from Allegra to Claritin. "Usage data about newer therapies is important for managed care organizations to analyze so they can understand physician and patient preferences," said Lewis Roht, M.D., Director of Drug Surveillance and Epidemiology at Hoechst Marion Roussel.

Other Studies
Other data presented at the ACAAI meeting by Hoechst Marion Roussel included:

  • A four-week, multicenter, double-blind, randomized, placebo-controlled study which showed that Allegra at doses of 20, 60, 120, and 240 mg reduced pruritus and number of wheals scores over a four-week period for the treatment of chronic idiopathic urticaria (CIU), also known as hives. The study demonstrated that all doses of Allegra greatly reduced the symptoms compared to placebo (P0.0115). Additionally, patients who received Allegra experienced significantly less interference with sleep and daily activities than patients who received placebo (P0.0014). Twice-daily doses of 60 mg or greater were most effective. Adverse events occurred with similar incidence in all treatment groups, with
    '"/>


Contact: Suzanne Wiele
816-966-3475
Porter Novelli
12-Nov-1999


Page: 1 2

Related medicine news :

1. Study of energy and health in Africa focuses spotlight on charcoal and forest management
2. Study shows promise in identifying kidney failure
3. Study shows patch therapy may be as effective as oral medications
4. Study shows soy is well accepted in school lunches
5. Study finds that coordinating care of chronically ill patients does not increase liability
6. Study provides new estimates of the causes of child mortality worldwide
7. Study finds factors linked to substance use disorder relapse among health care professionals
8. Study finds majority of women willing to accept cervical cancer vaccine for self and children
9. Study shows use of budesonide reduced the risk of asthma related events by 40% in children
10. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased
11. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women

Post Your Comments:
(Date:2/28/2015)... MD (PRWEB) February 28, 2015 The ... present its annual awards at the International Symposium on ... will be held at the Hyatt Regency Bethesda in ... for their dedicated work and commitment to the mission ... the Year Award will be presented to Miriam Ratner. ...
(Date:2/28/2015)... St. Louis, MO (PRWEB) February 28, 2015 ... a leading provider of outsourced sales, marketing and ... announces their client, BIOTA Botanicals, is bringing its ... , Celebrated worldwide, BIOTA Botanicals’ products are specifically ... the herbal care experts, BIOTA is committed to ...
(Date:2/28/2015)... Orlando, FL (PRWEB) February 28, 2015 ... community organization has sponsored visitor health insurance programs for ... 25 years. Most Indian elderly parents traveling to the ... conditions such as diabetes and blood pressure. These diseases ... do not even list them as medical conditions. There ...
(Date:2/28/2015)... Flagstaff, AZ (PRWEB) February 28, 2015 ... drug and alcohol treatment center , and current student ... State University, has implemented a weekly forum in psychoeducation ... high school in Flagstaff, AZ as part of her ... a big need for support and counseling at the ...
(Date:2/28/2015)... On Thursday, February 26th, Forbes published an ... Scammers To Steal Your Data , which stresses the ease ... a DIY phishing kit, or any kind of malware kit ... important point about how everyone’s cyber security is intertwined when ... compromising legitimate content management systems or blogs in order to ...
Breaking Medicine News(10 mins):Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 3Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 3Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 4
(Date:2/27/2015)... -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today ... the fourth quarter and full year ended December 31, ... for PTC. We are now a growing commercial-stage biopharma ... the rare disease space," stated Stuart W. Peltz, Ph.D., ... to bring the first treatment for Duchenne muscular dystrophy ...
(Date:2/27/2015)... and JERUSALEM , Feb. 27, ... developing octreotide capsules, its lead product for the orphan ... million Series E financing round. Participants in the financing ... and an undisclosed blue chip public investment fund, as ... Med Health Ventures, Abingworth and ARCH Venture Partners. ...
(Date:2/26/2015)... CHICAGO, Ill. , Feb. 26, 2015 /PRNewswire/ ... that 15 abstracts of studies in its neuroscience ... presentation during the 67 th American Academy ... D.C. , from April 18-25. The accepted ... product, DUOPA, in addition to investigational treatments in ...
Breaking Medicine Technology:PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 4AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 6AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 7
Cached News: